These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31295448)

  • 1. Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone.
    Adeyanju OA; Falodun TO; Fabunmi OA; Olatunji LA; Soladoye AO
    Chem Biol Interact; 2019 Sep; 310():108742. PubMed ID: 31295448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS.
    Olaniyi KS; Oniyide AA; Adeyanju OA; Ojulari LS; Omoaghe AO; Olaiya OE
    Toxicol Appl Pharmacol; 2021 Jan; 411():115381. PubMed ID: 33359182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe.
    Adeyanju OA; Falodun TO; Michael OS; Soetan OA; Oyewole AL; Agbana RD
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Jun; 393(6):1055-1066. PubMed ID: 31925474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor blockade attenuates hyperandrogenic metabolic dysregulation in letrozole-induced PCOS rat model.
    Uhunmwangho EG; Oniyide AA; Areloegbe SE; Soetan OA; Akintayo CO; Aturamu A; Olaniyi KS
    J Diabetes Metab Disord; 2022 Dec; 21(2):1539-1547. PubMed ID: 36404823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.
    Ryan GE; Malik S; Mellon PL
    Endocrinology; 2018 Apr; 159(4):1734-1747. PubMed ID: 29471436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of GABA against metabolic and reproductive disturbances in letrozole induced polycystic ovarian syndrome in rats.
    Ullah A; Jahan S; Razak S; Pirzada M; Ullah H; Almajwal A; Rauf N; Afsar T
    J Ovarian Res; 2017 Sep; 10(1):62. PubMed ID: 28915843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model.
    Peter MU; Areloegbe SE; Akintayo CO; Oniyide AA; Aturamu A; Olaniyi KS
    Can J Physiol Pharmacol; 2022 Sep; 100(9):890-902. PubMed ID: 35771488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model.
    Areloegbe SE; Peter MU; Oyeleke MB; Olaniyi KS
    BMC Endocr Disord; 2022 Sep; 22(1):224. PubMed ID: 36071485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agaricus Subrufescens ameliorates ovarian dysfunction and regulates altered biochemical parameters in rats with Letrozole induced polycystic ovarian syndrome.
    Bukke SPN; Pathange BBR; Karumanchi SK; Marri J; Boyina R; Rachamsetty K; Manchikalapati B; Odoma S; Hussaini B
    J Ovarian Res; 2023 Nov; 16(1):221. PubMed ID: 37993900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome.
    Olaniyi KS; Areloegbe SE; Areola ED; Sabinari IW; Fafure AA; Agbana RD; Atuma CL; Shah MZUH; Ajadi IO; Olatunji LA
    Toxicol Appl Pharmacol; 2023 Aug; 473():116604. PubMed ID: 37328115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ficus deltoidea ameliorates biochemical, hormonal, and histomorphometric changes in letrozole-induced polycystic ovarian syndrome rats.
    Haslan MA; Samsulrizal N; Hashim N; Zin NSNM; Shirazi FH; Goh YM
    BMC Complement Med Ther; 2021 Nov; 21(1):291. PubMed ID: 34844580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
    Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
    Vieira CS; Martins WP; Fernandes JB; Soares GM; dos Reis RM; de Sá MF; Ferriani RA
    Contraception; 2012 Sep; 86(3):268-75. PubMed ID: 22464410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Rat Model of Polycystic Ovary Syndrome with Insulin Resistance Induced by Letrozole Combined with High Fat Diet.
    Wang MX; Yin Q; Xu X
    Med Sci Monit; 2020 May; 26():e922136. PubMed ID: 32448863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism.
    Rajan RK; M SS; Balaji B
    Pharm Biol; 2017 Dec; 55(1):242-251. PubMed ID: 27927075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
    Gökmen O; Senöz S; Gülekli B; Işik AZ
    Gynecol Endocrinol; 1996 Aug; 10(4):249-55. PubMed ID: 8908525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome.
    Studen KB; Sebestjen M; Pfeifer M; Prezelj J
    Eur J Endocrinol; 2011 Mar; 164(3):389-95. PubMed ID: 21156647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone as a single agent for long-term therapy of hirsute patients.
    Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
    Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
    Kulshreshtha B; Gupta N; Ganie MA; Ammini AC
    Gynecol Endocrinol; 2012 Oct; 28(10):823-6. PubMed ID: 22475072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.